Show simple item record Szarvas, Tibor Sevcenco, S Módos, Orsolya Keresztes, Dávid Nyirády, Péter Csizmarik, Anita Ristl, R Puhr, M Hoffmann, MJ Niedworok, C Hadaschik, B Maj-Hes, A Shariat, SF Kramer, G 2019-10-03T07:42:54Z 2019-10-03T07:42:54Z 2018
dc.identifier.citation journalVolume=122;journalIssueNumber=4;journalTitle=BJU INTERNATIONAL;pagerange=695-704;journalAbbreviatedTitle=BJU INT;
dc.identifier.uri doi:10.1111/bju.14415
dc.description.abstract PURPOSE: To assess the predictive value of pre-chemotherapy MMP-7, sFas, FasL serum levels as well as their changes during therapy. PATIENTS AND METHODS: Serum levels of MMP-7, Fas and FasL were determined by ELISA in 96 CRPC patients; 21 docetaxel-resistant who received one single series and 75 docetaxel-sensitive who received repeated series of docetaxel. In addition to the 96 pretreatment serum samples, 987 sera collected during chemotherapy were also analysed. RESULTS: Higher pretreatment serum MMP-7, sFas and PSA levels were significantly associated with both docetaxel-resistance (p=0.007, p=0.001, p<0.001, respectively) and shorter cancer-specific survival (p<0.001, p=0.041, p<0.001, respectively). High MMP-7 remained an independent predictor of both docetaxel resistance (HR: 2.298, 95% CI: 1.354-3.899, p=0.002) and poor cancer-specific survival (HR=2.11, 95%Cl 1.36-3.30, p=0.001) in multivariable analyses. Higher increase of MMP-7 levels in the 2(nd) treatment holiday and higher increase of PSA levels in the 1(st) and 2(nd) holidays were predictive of survival. CONCLUSIONS: Pretreatment serum MMP-7 levels may help to select CRPC patients who are likely to benefit from docetaxel chemotherapy. Furthermore, MMP-7 alone or in combination with PSA could be used for therapy monitoring. Correlative studies embedded in clinical trials are necessary to validate these biomarkers for clinical decision-making. This article is protected by copyright. All rights reserved.
dc.format.extent 695-704
dc.relation.ispartof urn:issn:1464-4096
dc.title MMP-7, sFas and FasL serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer
dc.type Journal Article 2019-09-12T18:58:52Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 3381488
dc.identifier.wos 000445451300025
dc.identifier.pubmed 29802777
dc.contributor.department SE/AOK/K/Urológiai Klinika
dc.contributor.institution Semmelweis Egyetem

Files in this item

This file is available only from Semmelweis network


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account